Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. ToolGen Incorporated
  6. News
  7. Summary
    A199800   KR7199800004

TOOLGEN INCORPORATED

(A199800)
SummaryChartsNewsCompanyConsensus 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ToolGen, Inc. Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 System in vivo Genome Editing

02/22/2017 | 08:30am EDT

ToolGen Inc. announced encouraging data from a study evaluating Campylobacter jejuni Cas9 (CjCas9), the smallest Cas9 orthologue characterized to date, for efficient genome editing in vivo. The study was led by researchers from ToolGen, Dr. Jin-soo Kim, Principal Investigator, from the Institute for Basic Science and Dr. Jeong Hun Kim from Seoul National University Hospital. The study demonstrated the ability to package the CjCas9 gene, its sgRNA sequence into a single Adeno-associated virus (AAV) vector for in vivo gene surgery. Furthermore, CjCas9 was shown to be highly specific in cleaving the target sites in the human or mouse genome in vitro, which could have significant potential precision genome editing and gene surgery. CjCas9 delivered via AAV, induced target mutations in mouse muscle cells and retinal pigment epithelium cells (RPE) with no off-target mutations detected in the genome. The study confirmed that CjCas9 targeted to the Vegfa or Hif1a gene in RPE cells reduced the size of laser-induced choroidal neovascularization, a condition leading to the formation of new blood vessels in the choroid layer of the eye. This suggests that gene surgery with CjCas9 could be a promising treatment option for age-related macular degeneration, a leading cause of blindness in adults.


ę S&P Capital IQ 2017
All news about TOOLGEN INCORPORATED
2018ToolGen, Inc., Demonstrates CRISPR/Cas9 Gene Editing Improves Anti-Tumor Activity of Hu..
CI
2017Monsanto Company and ToolGen, Inc. Announce Global Licensing Agreement on CRISPR Platfo..
CI
2017ToolGen, Inc. Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 Sys..
CI
2016ToolGen Incorporated announced that it has received KRW 10.0223744 billion in funding
CI
2016ToolGen Incorporated announced that it expects to receive KRW 10.0223744 billion in fun..
CI
More news
Chart TOOLGEN INCORPORATED
Duration : Period :
ToolGen Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 144 300,00 
Average target price
Spread / Average Target -
Managers and Directors
Byung-Hwa Lee Co-Chief Executive Officer & Director
Young-Ho Kim Co-Chief Executive Officer & Director
Il-Ho Ha Independent Director
Seok-Joong Kim Director & Head-Business Development
Jong-Hyun Jang Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
TOOLGEN INCORPORATED30.00%815
MODERNA, INC.291.35%165 027
LONZA GROUP AG26.86%57 923
IQVIA HOLDINGS INC.38.49%47 547
CELLTRION, INC.-26.60%31 003
SEAGEN INC.-7.21%29 566